Circadian Rhythm Disruption Effects on Smoke Inhalation
The Effects of Circadian Rhythm Disruption on the Inflammatory Response to Particulate Matter Exposure From Woodsmoke
1 other identifier
interventional
10
1 country
1
Brief Summary
Particulate matter exposure during smoke inhalation provokes inflammatory immune responses in people exposed to burning biomass including fire fighters and civilians. Persistent occupational exposure to particulate matter represents a unique hazard for firefighters, underpinning a burgeoning research area. This trial will evaluate the effects of sleep deprivation and circadian rhythm disruption on the inflammatory response to woodsmoke associated particulate matter exposure. Participants will undergo 2 experimental trials in a randomized cross-over design. Participants will have either an 8-hour sleep opportunity or a 4-hour sleep opportunity prior to reporting to lab for a 45 minute simulated firefighting trial (wood smoke associated particulate matter filtered to 2.5 um at a concentration of 250 ug/m\^3, while exercising at a moderate intensity). The effects of sleep restriction and simulated firefighting will be measured.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 21, 2021
CompletedFirst Posted
Study publicly available on registry
July 8, 2021
CompletedStudy Start
First participant enrolled
January 24, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 17, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 17, 2022
CompletedResults Posted
Study results publicly available
May 30, 2025
CompletedMay 30, 2025
May 1, 2025
2 months
June 21, 2021
April 6, 2023
May 12, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Blood Inflammation
IL-6 will be measured in the plasma
samples collected at baseline, immediately post exposure
Secondary Outcomes (1)
Exhaled Breath Condensate Pentraxin-3
samples collected at baseline, immediately post exposure
Study Arms (2)
Normal Sleep (with 250 ug/m^3 PM2.5)
PLACEBO COMPARATORParticipants will have a normal sleep opportunity the night prior to reporting to the lab for the simulated firefighting session (250 ug/m\^3 PM2.5 with moderate intensity exercise).
Restricted Sleep (with 250 ug/m^3 PM2.5)
EXPERIMENTALParticipants will have a restricted sleep opportunity (\~4 hours) the night prior to reporting to the lab for the simulated firefighting session (250 ug/m\^3 PM2.5 with moderate intensity exercise).
Interventions
Participants will be allowed \~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
Participants will be allowed \~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
Eligibility Criteria
You may qualify if:
- Healthy
- Male
- years of age
You may not qualify if:
- Preexisting cardiometabolic and/or pulmonary diseases
- Preexisting sleep disorder
- Smoking (current or within last year)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Montanalead
- University of Nevada, Las Vegascollaborator
Study Sites (1)
School of Integrative Physiology and Athletic Training
Missoula, Montana, 59812, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
Our study was limited by a smaller sample size than we had anticipated.
Results Point of Contact
- Title
- Dr. John Quindry
- Organization
- University of Montana
Study Officials
- PRINCIPAL INVESTIGATOR
John C Quindry, PhD
University of Montana
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor and Chair
Study Record Dates
First Submitted
June 21, 2021
First Posted
July 8, 2021
Study Start
January 24, 2022
Primary Completion
March 17, 2022
Study Completion
April 17, 2022
Last Updated
May 30, 2025
Results First Posted
May 30, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared with other researchers. Blinded anonymized outcomes data will be shared via publication and presentation of results.